Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Gains from Investment Securities (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Gains from Investment Securities for 11 consecutive years, with -$3.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities fell 44.56% to -$3.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$3.7 million, a 55.09% increase, with the full-year FY2025 number at -$3.7 million, down 44.45% from a year prior.
  • Gains from Investment Securities was -$3.7 million for Q4 2025 at Cartesian Therapeutics, down from $2.5 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $16.7 million in Q1 2021 to a low of -$21.0 million in Q4 2022.
  • A 5-year average of -$1.8 million and a median of -$2.4 million in 2023 define the central range for Gains from Investment Securities.
  • Biggest YoY gain for Gains from Investment Securities was 1674800.0% in 2021; the steepest drop was 46619.44% in 2021.
  • Cartesian Therapeutics' Gains from Investment Securities stood at -$9.0 million in 2021, then tumbled by 133.76% to -$21.0 million in 2022, then skyrocketed by 68.15% to -$6.7 million in 2023, then skyrocketed by 61.83% to -$2.6 million in 2024, then crashed by 44.56% to -$3.7 million in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Gains from Investment Securities are -$3.7 million (Q4 2025), $2.5 million (Q3 2025), and -$2.5 million (Q2 2025).